8 research outputs found
Kaplan-Meier estimates of risk of selective tenofovir discontinuation in boosted protease inhibitors versus non-nucleoside reverse transcriptase inhibitors groups.
<p>Kaplan-Meier estimates of risk of selective tenofovir discontinuation in boosted protease inhibitors versus non-nucleoside reverse transcriptase inhibitors groups.</p
(a,b,c) Multivariable Cox regression analysis assessing factors associated with tenofovir discontinuation regardless of the reason, because of toxicity and with selective tenofovir discontinuation.
<p>(a,b,c) Multivariable Cox regression analysis assessing factors associated with tenofovir discontinuation regardless of the reason, because of toxicity and with selective tenofovir discontinuation.</p
Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–All tenofovir discontinuations.
<p>Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–All tenofovir discontinuations.</p
Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–Selective tenofovir discontinuations.
<p>Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–Selective tenofovir discontinuations.</p
Characteristics of the patients initiating a tenofovir-containing regimen, grouped by “third drug” class.
<p>Characteristics of the patients initiating a tenofovir-containing regimen, grouped by “third drug” class.</p
Mean eGFR annual change (ml/min) among patients developing mild renal impairment during treatment with tenofovir.
<p>Results from the GEE multivariate linear model.</p
Characteristics of patients developing mild renal impairment under TDF.
<p>Characteristics of patients developing mild renal impairment under TDF.</p
Association between current TDF use and CKD, based on cumulative exposure to TDF after mild renal impairment occurrence.
<p>eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0162320#pone.0162320.ref008" target="_blank">8</a>] Chronic Kidney Disease was defined as two eGFR <60 ml/min measured 3–6 months apart. Abbreviations: CI, confidence interval; CKD, chronic kidney disease; TDF, tenofovir disoproxil fumarate.</p